TOP TEN perturbations for 39997_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39997_at
Selected probe(set): 206380_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39997_at (206380_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
IL-4; GM-CSF study 1 (late) / untreated monocyte sample
Relative Expression (log2-ratio):-4.782382Number of Samples:6 / 12
| Experimental | IL-4; GM-CSF study 1 (late) |
| Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3. | |
| Control | untreated monocyte sample |
| Freshly isolated human monocytes from healthy donors. |
LPS study 4 / mock treated MONO-MAC-6 cell sample
Relative Expression (log2-ratio):3.8974915Number of Samples:2 / 2
| Experimental | LPS study 4 |
| MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | mock treated MONO-MAC-6 cell sample |
| MONO-MAC-6 (MM6) cells mock treated. |
precursor-B-ALL study 1 (t(12;21)(p12,q22)) / normal bone marrow sample
Relative Expression (log2-ratio):-3.7113562Number of Samples:58 / 74
| Experimental | precursor-B-ALL study 1 (t(12;21)(p12,q22)) |
| Bone marrow samples of patients with precursor B-ALL (t(12;21)(p12,q22)/TEL-AML1). | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |
MALT lymphoma study 1 / normal spleen tissue
Relative Expression (log2-ratio):-3.620575Number of Samples:8 / 6
| Experimental | MALT lymphoma study 1 |
| Human t(11;18)-negative mucosa-associated lymphoid tissue (MALT) lymphoma cells. | |
| Control | normal spleen tissue |
| Normal human spleen tissue sample. |
precursor-B-ALL study 1 (t(1;19)(q23,q13)) / normal bone marrow sample
Relative Expression (log2-ratio):-3.564289Number of Samples:36 / 74
| Experimental | precursor-B-ALL study 1 (t(1;19)(q23,q13)) |
| Bone marrow samples of patients with precursor B-ALL (t(1;19)(q23,q13)/E2A-PBX1). | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |
IL-4; GM-CSF study 1 (intermediate) / untreated monocyte sample
Relative Expression (log2-ratio):-3.3166513Number of Samples:7 / 12
| Experimental | IL-4; GM-CSF study 1 (intermediate) |
| Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 24 hours. | |
| Control | untreated monocyte sample |
| Freshly isolated human monocytes from healthy donors. |
LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):3.3049908Number of Samples:2 / 2
| Experimental | LPS study 4 (shRNA contr.) |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | mock treated / transduced MONO-MAC-6 cell sample |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
LPS study 4 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)
Relative Expression (log2-ratio):3.2510786Number of Samples:2 / 2
| Experimental | LPS study 4 (shRNA cycT1) |
| MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | cycT1 depletion study 2 (shRNA) |
| MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated. |
c-ALL/pre-B-ALL study 1 / normal bone marrow sample
Relative Expression (log2-ratio):-3.224615Number of Samples:232 / 74
| Experimental | c-ALL/pre-B-ALL study 1 |
| Bone marrow samples of patients with c-ALL/pre-B-ALL (without t(9;22)(q34,q11)/BCR-ABL). | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |
HCV-related HCC study 1 / adjacent HCV-related liver tissue (LC)
Relative Expression (log2-ratio):-3.1442633Number of Samples:5 / 4
| Experimental | HCV-related HCC study 1 |
| Hepatitis C infection related human hepatocellular carcinoma sample. | |
| Control | adjacent HCV-related liver tissue (LC) |
| Histologically normal adjacent liver tissue of a patient with Hepatitis C infection related hepatocellular carcinoma. Patient with liver cirrhosis. |
Organism: Homo sapiens
Gene: 39997_at
Selected probe(set): 206380_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39997_at (206380_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
IL-4; GM-CSF study 1 (late) / untreated monocyte sample
Relative Expression (log2-ratio):-4.782382Number of Samples:6 / 12
| Experimental | IL-4; GM-CSF study 1 (late) |
| Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3. | |
| Control | untreated monocyte sample |
| Freshly isolated human monocytes from healthy donors. |
LPS study 4 / mock treated MONO-MAC-6 cell sample
Relative Expression (log2-ratio):3.8974915Number of Samples:2 / 2
| Experimental | LPS study 4 |
| MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | mock treated MONO-MAC-6 cell sample |
| MONO-MAC-6 (MM6) cells mock treated. |
precursor-B-ALL study 1 (t(12;21)(p12,q22)) / normal bone marrow sample
Relative Expression (log2-ratio):-3.7113562Number of Samples:58 / 74
| Experimental | precursor-B-ALL study 1 (t(12;21)(p12,q22)) |
| Bone marrow samples of patients with precursor B-ALL (t(12;21)(p12,q22)/TEL-AML1). | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |
MALT lymphoma study 1 / normal spleen tissue
Relative Expression (log2-ratio):-3.620575Number of Samples:8 / 6
| Experimental | MALT lymphoma study 1 |
| Human t(11;18)-negative mucosa-associated lymphoid tissue (MALT) lymphoma cells. | |
| Control | normal spleen tissue |
| Normal human spleen tissue sample. |
precursor-B-ALL study 1 (t(1;19)(q23,q13)) / normal bone marrow sample
Relative Expression (log2-ratio):-3.564289Number of Samples:36 / 74
| Experimental | precursor-B-ALL study 1 (t(1;19)(q23,q13)) |
| Bone marrow samples of patients with precursor B-ALL (t(1;19)(q23,q13)/E2A-PBX1). | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |
IL-4; GM-CSF study 1 (intermediate) / untreated monocyte sample
Relative Expression (log2-ratio):-3.3166513Number of Samples:7 / 12
| Experimental | IL-4; GM-CSF study 1 (intermediate) |
| Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 24 hours. | |
| Control | untreated monocyte sample |
| Freshly isolated human monocytes from healthy donors. |
LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):3.3049908Number of Samples:2 / 2
| Experimental | LPS study 4 (shRNA contr.) |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | mock treated / transduced MONO-MAC-6 cell sample |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
LPS study 4 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)
Relative Expression (log2-ratio):3.2510786Number of Samples:2 / 2
| Experimental | LPS study 4 (shRNA cycT1) |
| MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | cycT1 depletion study 2 (shRNA) |
| MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated. |
c-ALL/pre-B-ALL study 1 / normal bone marrow sample
Relative Expression (log2-ratio):-3.224615Number of Samples:232 / 74
| Experimental | c-ALL/pre-B-ALL study 1 |
| Bone marrow samples of patients with c-ALL/pre-B-ALL (without t(9;22)(q34,q11)/BCR-ABL). | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |
HCV-related HCC study 1 / adjacent HCV-related liver tissue (LC)
Relative Expression (log2-ratio):-3.1442633Number of Samples:5 / 4
| Experimental | HCV-related HCC study 1 |
| Hepatitis C infection related human hepatocellular carcinoma sample. | |
| Control | adjacent HCV-related liver tissue (LC) |
| Histologically normal adjacent liver tissue of a patient with Hepatitis C infection related hepatocellular carcinoma. Patient with liver cirrhosis. |